Cargando…
Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study
Cyclosporine A (CsA) is commonly used for Graft versus Host Disease (GvHD) prophylaxis at a recommended starting dose of 3 mg/kg/d: Evidence for the effect of different CsA starting doses on GvHD risk is limited. We therefore estimated the association of 5 mg/kg/d (CsA5) and 3 mg/kg/d (CsA3) CsA sta...
Autores principales: | Héritier, Jérémie, Medinger, Michael, Heim, Dominik, Baldomero, Helen, Arranto, Christian, Halter, Jörg P., Passweg, Jakob R., Kleber, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993684/ https://www.ncbi.nlm.nih.gov/pubmed/35132203 http://dx.doi.org/10.1038/s41409-022-01598-6 |
Ejemplares similares
-
Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019) -
Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation
por: Szyska, Martin, et al.
Publicado: (2016) -
Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015) -
Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022) -
External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study
por: Fattinger, Nicolas, et al.
Publicado: (2022)